HeartWare International (NSDQ:HTWR) shares gained 15% this morning after the medical device company crushed forecasts with its 3rd-quarter sales and earnings figures, reporting stronger-than-expected sales of its left ventricular assist device implantable heart pump.
Q3
Endo Health announces a lifesciences mega-buy and Street-beating Q3
There are big things afoot at Endo Health Solutions (NSDQ:ENDP), which announced plans to pick up specialty pharmaceuticals maker Paladin Labs in a deal valued at $1.6 billion.
Hospira beats The Street with 3rd-quarter earnings
Mako’s Q3 numbers drop, outlook clears in the midst of Stryker merger
Abiomed flirts with 52-week high on Q2 results
Endologix posts Q3 sales surge but losses widen
Endologix (NSDQ:ELGX) posted sales growth of nearly 25% during the 3rd quarter, but losses widened by nearly 58%.
Irvine, Calif.-based Endologix posted losses of $9.5 million, or 14¢ per share, on sales of $33.3 million for the 3 months ended Sept. 30. That’s a profit slide of 57.9% on sales growth of 24.6% compared with the same period last year.
Staar Surgical swings to Q3 black
Staar Surgical (NSDQ:STAA) put black ink into its ledger for the 3rd quarter, beating Wall Street’s earnigns expectations in the process.
FDA will hold dispute resolution panel for Wright Medical’s rejected Augment bone graft
Wright Medical (NSDQ:WMGI) officials said the FDA has agreed to hold a dispute resolution panel for the orthopedic company’s Augment Bone Graft product, which was denied approval by the agency in August.
Volcano management discusses Q3 earnings results
ConMed battles ‘activist investor’ amid harsh quarter, lowered forecast
Corrected November 11 2013, at 2:45 p.m.